The Rs 800 crore Elder Pharmaceuticals Limited, manufacturer of superbrand
calcium supplement ShelCal, plans to launch almost 3 dozen new products in the
coming 30 months in niche therapeutic segments like female healthcare,
osteoporosis, Dermatology, pain management, Cardiology, nutraceuticals, wound
care and vitamin supplements. This will consist of a combination of in-licensed
and own products although the larger focus will be on self-researched products.
The company has a state-of-the-art Research & Development Centre at Navi
Mumbai which is recognized by the Department of Scientific & Industrial
Research, Ministry of Science & Technology. The R&D centre has recently
been modernized and expanded and now consists of about 100 scientists.
Says Alok Saxena, Director, Elder
Pharmaceuticals Ltd, "We are looking at launching atleast 8-9
products each in the Women’s healthcare & Nutraceuticals segments which are
growing at an average of 18-20% annually - higher than the 12-13% growth rate
of the overall domestic pharma industry. Our scientists are also working on new
products, new drug delivery systems and combination therapies in niche
therapeutic segments like osteoporosis, dermatology, cardiology, pain
management, would care, vitamin supplements etc and we hope to launch atleast
3-4 new products in each of these segments." The balance launches will be
in-licensed products. The company has earmarked an investment of about Rs
120-130 crore for this.
The company is also looking at the wound care & pain management segments
which currently contribute about 16% to Elder’s turnover and anticipated to
grow at over 15% every year. The mantra in these segments will be launch of
therapies which are non-invasive and having little or no side effects.
For Elder, major developments during FY 2011 were the hiking of stake in its
overseas acquisitions viz Neutra Health plc of UK [to 100%] and Elder Biomeda
of Bulgaria [to 92%] and getting accreditation from Ministry of Japan for its
state-of-the-art plant at Patalganga (Maharashtra). Following the
accreditation, Elder has developed two products going off patent in the
Japanese market in 2014. One of the products is from the CNS (Cerebro
Neuropsychiarty Segment) category and the second is from the GI (Gastro
Intestinal) segment. Elder has already filed a PCT patent [an international
patent application] for one of the advanced intermediates for the Japanese
market and is in talks with Japanese generic companies for supply contracts.
Elder Pharma is targeting a turnover of Rs 1500 cr by 2013.
About Elder Pharmaceuticals Limited:
Elder Pharmaceuticals Limited [NSE: ELDERPHARM] has presence in niche therapeutic
segments like Women’s healthcare, Wound care, Nutraceuticals /vitamin
Supplements, Cardiology, Diabetes, Dermatology, Antibiotics and CNS. It is the
market leader in calcium supplements (Shelcal), wound healing and injectable
B12 vitamin. The company also has substantial interests in Medical Devices and
non-pharmaceutical medical products. The company has a judicious mix of drug
formulations, and active pharma ingredients (APIs). It has 7 manufacturing
plants in India located in Maharashtra, Uttarakhand & Himachal Pradesh.
Contact:
Mitesh M Kapadia
Sentinel Public Relations Pvt Ltd / Sentinel Advertising Services
B-603, Samajdeep, Near Bhanu Park/Seasons Restaurant
Adukia Road, Off S V Road
Kandivli (W), Mumbai 400 067 India
Mob: +91 98205 03876 begin_of_the_skype_highlighting +91 98205 03876 end_of_the_skype_highlighting
Tel: (022) 28625131/32
Fax: (022) 28625133
